• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears expansion of CeloNova’s nano-coated coronary stent trial

October 26, 2017 By Sarah Faulkner

Celonova BiosciencesCeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding.

The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day DAPT following percutaneous coronary intervention.

“High bleeding risk patients currently have limited stent treatment options available to them primarily due to the duration of DAPT required,” co-lead investigator Dr. Robert Byrne said in prepared remarks. “The Cobra Reduce trial aims to provide clinical insights into optimal stent selection and eliminate the compromise between the risk of bleeding or stent thrombosis.”

The trial is slated to compare CeloNova’s Cobra device, which is composed of an ultra-thin polyzene-F fluoropolymer, with FDA-approved drug-eluting stents. The 996-patient study will assess whether the nano-coated coronary stent can improve clinical outcomes with 14 days of DAPT compared to drug-eluting stents with three or six months of DAPT.

“The highly-anticipated Cobra Reduce trial aims to expand upon the Shield study’s exceptional clinical results and demonstrate Cobra PzF NCS as a safe and effective stent option when combined with 14-days of DAPT,” Dr. Donald Cutlip, executive director of the Baim Institute for Clinical Research, said. “I have many patients at high risk of bleeding or who have difficulty maintaining even short-term DAPT regimens. Being able to provide a therapy that is personalized to the patient is of great clinical value.”

“We are pleased that the Cobra PzF stent and the Cobra Reduce trial are part of the important DAPT discussion taking place at the upcoming TCT conference,” CEO Jason Cone added. “Results from this first-of-its-kind study will offer insight into how CeloNova can further improve individualized care and optimize outcomes in this patient population.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Vascular Tagged With: celonova

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS